TOLLYS develops TolX100, an innovative immunotherapy targeting Toll-Like Receptor 3 (TLR3) in the field of cancer.
TOLLYS SAS
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Website
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
AddressUnited States
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]